Vitiligo

Latest News

VYN201 for Vitiligo: Promising Data Showcases Potential of BET Inhibition
VYN201 for Vitiligo: Promising Data Showcases Potential of BET Inhibition

May 22nd 2024

VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.

VYNE Therapeutics Provides Updates on VYN201 for Nonsegmental Vitiligo and VYN202 for Inflammatory Diseases
VYNE Therapeutics Provides Updates on VYN201 for Nonsegmental Vitiligo and VYN202 for Inflammatory Diseases

May 9th 2024

Topical Antibiotic Treatment Significantly Reduced Depigmentation in Mouse Model
Topical Antibiotic Treatment Significantly Reduced Depigmentation in Mouse Model

May 8th 2024

Patients With Vitiligo Have Decreased Risk of Subsequent Pulmonary Embolism, Peripheral Vascular Disease
Patients With Vitiligo Have Decreased Risk of Subsequent Pulmonary Embolism, Peripheral Vascular Disease

May 7th 2024

JAK Inhibitors Show Favorable Risk-Benefit Profile In Vitiligo, Especially for Facial Cases
JAK Inhibitors Show Favorable Risk-Benefit Profile In Vitiligo, Especially for Facial Cases

May 2nd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.